StockWire X

Glass the thickness of a mobile phone with the thermal performance of 1.5 metres of brick wall - that's what ClearVue and LandVac are putting to the test right now.

ClearVue Technologies (ASX: CPV) has commenced the first real-world deployment of its jointly developed photovoltaic glazing technology at a hotel in Macau, marking the transition of Project Delta from product development into live validation. The deployment uses a Measurement and Verification methodology, replacing an existing legacy single-glazed window with the new technology while an adjacent room retains the original glazing as a direct side-by-side control. Sensors will simultaneously measure electricity generation, thermal performance, and air-conditioning energy consumption under comparable real operating conditions.

CEO Doug Hunt noted: "This deployment demonstrates the early ex*****on of our joint venture with LandVac and represents an important step in taking our jointly developed technology from product development into real-world validation." Macau's subtropical climate makes it a strategically relevant test environment, given that high heat and humidity amplify performance differences between glazing systems. The technology claims 20% less solar heat gain, roughly three times the efficiency of standard double glazing, and approximately 12 times the efficiency of the legacy single glazing it is replacing - with independent engineering support from erbas providing external validation of results.

Read the full breakdown of Project Delta, the Macau deployment structure, and what independent M&V data means for the commercial pathway: https://stockwirex.com/asx-stock-news/industrials/cpv-clearvue-technologies-project-delta-deployment-september-2026/

The Queensland Government has extended The Star Gold Coast's licence suspension deferral to 31 March 2027 — and for SGR investors, the distinction between a deferral and an actual suspension is everything.

The Crisafulli Government has pushed back the potential licence suspension at The Star Gold Coast from 30 September 2026 to 31 March 2027, following advice from Special Manager Nicholas Weeks, including his August Report on SGR's remediation progress. In a parallel move, the External Advisor appointment at The Star Brisbane has also been extended to the same date, maintaining independent oversight across both Queensland properties. Critically, this is not a suspension or cancellation — it is a continued conditional operating window, meaning both properties remain open for business and generating revenue.

Attorney-General Deb Frecklington stated: "Those expectations remain unchanged, and while I acknowledge the work of The Star to date, this extension will allow The Star to further demonstrate its delivery on key remediation commitments under the agreement." Weeks' August Report acknowledged significant progress across organisational and financial reforms, though several priority remediation matters remain in progress — this is not a clean bill of health. The March 2027 deadline is now the critical milestone for SGR investors, as it will determine whether the deferral is extended again, the suspension lifted, or ultimately enacted.

Read the full regulatory breakdown and what the next six months mean for SGR's investment case: https://stockwirex.com/asx-stock-news/consumer-discretionary/sgr-star-entertainment-group-gold-coast-licence-deferral-september-2026/

ClearVue Technologies has just commenced the first real-world deployment of its jointly developed ClearVue-LandVac photovoltaic glazing technology — and the test environment couldn't be more demanding.

Project Delta is a single-glazed insulating photovoltaic window designed as a direct replacement for legacy single glazing in existing buildings. CEO Doug Hunt describes it as roughly 12 times more thermally efficient than legacy single glazing, delivering a 20% lower solar heat gain coefficient, all in a profile approximately the thickness of a mobile phone. The installation is underway at a hotel in Macau under a Letter of Intent, with one room fitted with the Project Delta window and an adjacent room retaining legacy glazing for a direct side-by-side comparison.

LandVac Founder Mr ZHAO, Yan highlighted why Macau's subtropical heat and humidity make it the ideal proving ground: "Legacy single glazing allows significant heat transfer, driving up cooling loads in hot, humid climates, which makes Macau's subtropical conditions an ideal test environment." The deployment will measure electricity generation output, thermal performance, and air-conditioning energy consumption differences, with independent engineering firm erbas providing technical support. Mr ZHAO also signalled this hotel "certainly won't be the last" deployment, framing Macau as the first of multiple planned real-world validations.

Read the full technical breakdown of Project Delta and what this milestone means for ClearVue's commercial roadmap: https://stockwirex.com/asx-stock-news/industrials/cpv-project-delta-macau-solar-window-deployment/

FDA approval of a new potency assay may not sound headline-grabbing, but for Ryoncil's commercial scale-up, it's a significant manufacturing milestone.

Mesoblast has received FDA clearance to implement the T-cell Proliferation Inhibition BioAssay (TIBA) for the release and stability monitoring of all new commercial lots of Ryoncil, the first FDA-approved MSC therapy for steroid-refractory acute graft versus host disease in patients aged two months and older. TIBA joins two existing assays — IL-2Rα inhibition and CAP — forming a three-assay release matrix designed to ensure every commercial batch maintains consistent potency as production scales across existing and new manufacturing facilities.

The approval reflects ongoing regulatory collaboration between Mesoblast and the FDA since Ryoncil's commercial clearance, and directly enables batch release under the product's Biologics License. It comes as Ryoncil continues to build commercial momentum, with an 84% survival rate reported in its first commercial patient cohort and 45 transplant centres now onboarded across the US network. Beyond the approved paediatric indication, the company is advancing Ryoncil into adult SR-aGvHD and biologic-resistant inflammatory bowel disease, with broader pipeline programmes also progressing in parallel.

Read the full breakdown of what this regulatory milestone means for Ryoncil's manufacturing scale-up and commercial trajectory: https://stockwirex.com/asx-stock-news/biotech-health/msb-mesoblast-ryoncil-fda-potency-assay-september-2026/

FBR's Mantis® welding robot is hitting 120cm/min weld speeds - that's four times the contractual FAT minimum, and nearly ten times the pace of a human welder.

FBR Limited's (ASX: FBR) first DST®-powered Mantis® high deposition welding robot has completed construction, commissioning, and calibration, and is now in active welding trials ahead of its Factory Acceptance Test. The FAT is the sole remaining hurdle before payment is triggered and the unit ships to buyer State Machinery and Equipment Sales in Kenner, Louisiana - a $990,000 first sale secured under a milestone-based payment structure.

CEO Mark Pivac stated: "Our team has made excellent progress with the development of the DST®-powered Mantis® robot. We are achieving excellent weld quality and production speeds faster than human welders typically achieve." Beyond the first unit, FBR has appointed Industrial Robotics as its US distributor, with leads already in progress across Louisiana, Alabama, Mississippi, and the Florida Panhandle, plus demonstrations planned for Australian and global customers following FAT completion.

Read the full breakdown of the welding trial results, DST® technology, and what comes next for Mantis®: https://stockwirex.com/asx-stock-news/industrials/fbr-mantis-welding-robot-fat-breakthrough-september-2026/

A successful Mexican bank trial and a four-year renewal in New Zealand — RocketBoots is converting proof-of-concept work into real commercial traction.

RocketBoots (ASX: ROC) has confirmed a successful trial with a major Mexican retail bank operating more than 1,200 branches, with rollout discussions now underway alongside the multinational consulting partner that originated the opportunity. Separately, a New Zealand retail bank that first engaged the company in 2019 has renewed its software agreement for a further 12 months, with the invoice already paid. Combined invoices across both events total approximately A$231,000, including A$131,000 issued for the completed Mexican trial.

CEO Joel Rappolt stated: "The Mexican trial has done what it was set up to do. The customer has described the trial as successful, and we have started rollout discussions with them and with our consulting partner." The 1,200-branch network represents a potentially material revenue step-up if a rollout contract is agreed, though terms remain under negotiation. The consulting partner relationship is also significant — as a channel that could facilitate further introductions, it reduces the cost of customer acquisition for future opportunities.

Read the full analysis of what these developments mean for RocketBoots investors: https://stockwirex.com/asx-stock-news/tech-ai/roc-rocketboots-mexican-bank-trial-success-september-2026/

300,000 registered users and 70,000 added in under nine months — One Click Group's platform is hitting its stride.

One Click Group (ASX: 1CG) has surpassed 300,000 registered users on its One Click Life digital financial services platform, reflecting 30% growth year-to-date in 2026. Tax remains the core acquisition engine, drawing users onto the platform through which lending, wealth, and complementary financial products can then be introduced. The Little Money cash advance business is now moving into scale-up mode following a successful testing phase, while a new senior appointment is set to strengthen the company's lending capability.

Managing Director Mark Waller noted: "Surpassing 300,000 registered users is another important milestone and demonstrates the scale we have built in our user acquisition models. The opportunity now is to deepen those customer relationships by scaling our lending products, launching wealth products and broadening the financial services available through One Click Life." The strategic focus has shifted from user acquisition to monetisation — specifically growing the number of existing users who adopt multiple One Click products over time, a dynamic that compounds revenue per user without requiring proportional additional acquisition spend. The company already demonstrated improving unit economics in FY2025, when a 38% reduction in customer acquisition costs accompanied 26% revenue growth and a first positive underlying EBITDA result.

Read the full breakdown of One Click Group's five strategic priorities and what the 300,000-user milestone means for revenue conversion: https://stockwirex.com/asx-stock-news/industrials/1cg-one-click-group-300000-users-milestone-september-2026/

Stakk has done what it said it would do — A$55.2 million in FY2027 revenue is now 100% contracted, and the company's attention has already moved on.

Stakk Limited (ASX: SKK) has confirmed its full FY2027 pro-forma consolidated revenue forecast is secured under recurring customer contracts, with new international wins across Thailand, Italy, Dubai, Ireland and Scotland sitting on top of that contracted base. Those five markets are expected to principally contribute to FY2028 and beyond, meaning the pipeline for the following year is already taking shape before FY2027 has even begun. The company serves more than 300 enterprise customers and processes more than 110 billion interactions annually.

CEO Emiliano Giacchetti was direct about what the milestone means: "A$55.2 million is no longer the revenue we are trying to win. It is contracted. We have done what we said we would do, and our attention is already moving forward." That forward focus includes the November 2026 launch of Stakk International Pte Ltd in Singapore, which will serve as the global commercial and technology hub for all markets outside the United States, targeting gross margins of approximately 85% with infrastructure designed to scale alongside revenue rather than ahead of it.

Get the full breakdown of Stakk's contracted revenue position, Singapore strategy and FY2028 pipeline: https://stockwirex.com/asx-stock-news/communication-media/skk-stakk-ltd-fy2027-revenue-secured-september-2026/

Elixinol Wellness is making a calculated move into personalised health subscriptions — and global capital is already pricing this category in the billions.

Elixinol (ASX: EXL) has signed a binding term sheet to acquire Vitable, a quiz-driven supplement subscription platform with 7,851 active subscribers and 1.84 million quiz and recommendation records. The proposed deal would combine Elixinol's existing brands — H**p Foods Australia, Mt Elephant, and The Healthy Chef — with Vitable's direct-to-consumer health technology platform, creating a combined Group with A$20m+ in revenue from completion. Consideration is structured across three tranches totalling up to A$3.5m, with the majority deferred and tied to revenue growth or market capitalisation milestones.

The strategic logic centres on what Vitable adds beyond subscriber numbers: owned app, email, and subscription channels that reduce reliance on paid acquisition, plus a compounding data asset that management believes can drive cross-sell across the entire Group. The move positions Elixinol in a category attracting serious global attention — P&G acquired Thorne for US$3.8bn and Hims & Hers acquired Eucalyptus for up to US$1.15bn, both completed in 2026. Management has outlined an illustrative A$50m revenue ambition for the combined Group over a three-to-five-year horizon, though this is explicitly not guidance.

Get the full deal structure, strategic breakdown, and what this means for the path to completion: https://stockwirex.com/asx-stock-news/consumer-staples/exl-elixinol-wellness-vitable-acquisition-september-2026/

Ovarian cancer has the highest five-year mortality rate of all cancers affecting women — and there is still no population-level screening test for it. CLEO Diagnostics is working to change that.

ASX-listed CLEO Diagnostics (COV) has commenced prototype development of a multi-biomarker blood screening test targeting a $150B global addressable market for ovarian cancer population screening. The program runs in parallel with the company's pre-surgical triage test, which remains on track for FDA 510(k) submission in H1 CY2027 and addresses a separate $1.6B market. Initial proof-of-concept screening data is expected as early as the October–December 2026 quarter.

The development is underpinned by more than 15 years of CXCL10 biomarker research, meaning the screening program builds directly on existing IP and infrastructure rather than starting from zero. Access to two internationally significant biobanks — UKCTOCS via UCL and the U.S. PLCO collection — has already been secured, removing a common early-stage bottleneck. CLEO has also set exceptionally demanding performance thresholds before development began, including 99.6% specificity for general population screening, positioning the program for both clinical credibility and regulatory relevance from the outset.

Read the full breakdown of CLEO's dual-program strategy and upcoming milestones: https://stockwirex.com/asx-stock-news/biotech-health/cov-cleo-diagnostics-ovarian-cancer-screening-september-2026-2/